Estrogen and progesterone receptors in breast cancer - The current state of knowledge;Receptory estrogenowe i progesteronowe w raku piersi - Współczesny stan wiedzy

Wspolczesna Onkologia

Volumn 9, Issue 9, 2005, Pages 371-379

  Piekarski, Janusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Breast cancer; Estrogen receptor; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

BINDING ASSAY; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; GENETIC CODE; GENETIC TRANSCRIPTION; HORMONE ACTION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LIGAND BINDING; PHENOTYPE; PREDICTION; PROGNOSIS; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

EID: 30844439153     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Review

References (193)

1. Schinzinger A. Uber carcinoma mammae. Bericht uber die Verhandlundgen der Deutschen Gesellschaft fur Chirurgie. Kongressals Beilage zum Centralblatt fur Chir 1889; 29: 55. W: Bland KI, Copeland EM. The Breast, WB Sanders Company, Philadelphia, 1991.
2. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; ii: 104-7.
3. Allen E, Doisy EA. An ovarian hormone. Preliminary report on its localization, extraction and partial purification, and action in test animals. JAMA 1923; 81: 891-21.
4. Jensen EV. Proc Intl Congr Biochem, Vienna 1958. London, Pergamon Press. 1960.
5. Toft D, Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci U S A 1966; 55: 1574-81.
6. Jensen EV, Suzuki T, Kawashima T, et al. A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci U S A 1968; 59: 632-8.
7. Jensen EV, Block GE, Smith S, et al. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 1971; 34: 55-70.
8. Jensen EV. Steroid receptors in breast cancer: historical perspective. Cancer 1980; 46 (12 suppl.): 2759-61.
9. Korenman SG, Dukes BA. Specific estrogen binding by the cytoplasm for human breast carcinoma. J Clin Endocrinol Metab 1970; 30: 639-45.
10. Vashisht A, Studd JW. Molecular mechanisms of oestrogen - the gynaecologists' viewpoint. Eur J Cancer 2000; 36 suppl. 14: S14-5.
11. Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990; 9: 1603-14.
12. Branković-Magić M, Nikolić-Vukosavljević D, Neśković-Konstantinović Z, et al. Estrogen and progesterone receptor content in bilateral breast cancer. Pathol Res Pract 1995; 191: 16-24.
13. Clark GM, McGuire WL, Hubay CA, et al. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 1983; 309: 1343-7.
14. Fernö M, Badetorp B, Bendahl PO, et al. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen-especially for progesterone receptor positive tumors with a high proliferation. Breast Cancer Res Treat 1995; 36: 23-34.
15. EORTC Breast Cancer Group. Prognostic and predictive factors. W: Manual for clinical research in breast cancer. 5th ed. Glasgow, UK 2004: 38-42.
16. Thorpe SM. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance. Acta Oncol 1988; 27: 1-19.
17. Stierer M, Rosen H, Weber R, et al. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg 1993; 218: 13-21.
18. Stonelake PS, Baker PG, Gillespie WM, et al. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 1994; 30A: 5-11.
19. Takashima T, Onoda N, Ishikawa T, et al. Prognostic value of combined analysis of estrogen receptor status and cellular proliferative activity in breast cancer patients with extensive lymph node metastases. Oncol Rep 2002; 9: 589-94.
20. Ferrer Roca OF, Ramos A, Diaz Cardama A. Immunohistochemical correlation of steroid receptors and disease-free interval in 206 consecutive cases of breast cancer: validation of telequantification based on global scene segmentation. Anal Cell Pathol 1995; 9: 151-63.
21. Coradini D, Oriana S, Mariani L, et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer 1998; 34: 825-30.
22. Van Agthoven T, Timmermans M, Dorssers LC, et al. Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer. Int J Cancer 1995; 63: 790-3.
23. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005; 123: 21-7.
24. Stierer M, Rosen H, Weber R, et al. A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Breast Cancer Res Treat 1995; 36: 11-21.
25. Bozcuk H, Uslu G, Pe̊tereli E, et al. Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators. Breast Cancer Res Treat 2001; 68: 239-48.
26. Chow LW, Ho P. Hormonal receptor determination of 1,052 Chinese breast cancers. J Surg Oncol 2000; 75: 172-5.
27. Biesterfeld S, Schröder W, Steinhagen G, et al. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information. Anticancer Res 1997; 17: 4723-9.
28. Murphy LC, Peng B, Lewis A, et al. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 2005; 34: 553-66.
29. Matsumoto K. Progesterone and estrogen receptor in Japanese breast cancer. In: Hormones, Receptors and Breast Cancer. McGuire WL (ed.). Raven Press, New York, 1978: 43-58.
30. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992; 339: 71-85.
31. Elledge RM, Fuqua SA. Estrogen and progesterone receptors. In: JR Harris, ME Lippman, M Morrow and CK Osborne (eds). Diseases of the Breast. Vol. 2, Philadelphia: Lippincott, Williams & Wilkins, 2000: 471-88.
32. Reiner A, Neumeister B, Spona J, et al. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 1990; 50: 7057-61.
33. Pertschuk LP, Kim DS, Nayer K, et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 1990; 66: 1663-70.
34. Sunderland MC, McGuire WL. Hormones and breast cancer. Trends Endocrinol Metab 1991; 2: 72-6.
35. Manni A. Endocrine therapy of metastatic breast cancer. J Endocrinol Invest 1989; 12: 357-72.
36. Rutqvist LE, Cedermark B, Fornander T, et al. The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer. J Clin Oncol 1989; 7: 1474-84.
37. Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983; 1: 227-41.
38. Pertschuk LP, Feldman JG, Kim Y, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 1996; 77: 2514-9.
39. McGuire WL, Carbone PP, Sears ME, et al. Estrogen receptors I human breast cancer: an overview. In: McGuire WL, Carbone PP, Vollmer ER (eds). Estrogen Receptors in Human Breast Cancer. New York, Raven Press, 1975: 1-8.
40. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
41. Hayes FD, Henderson IC, Shapiro LC. Treatment of metastatic breast: present and future prospects. Sem Oncol 1995; 22 (suppl 5): 5-21.
42. Gorlich M, Jandrig B. Steroid hormone receptors and hormonal therapies in human breast cancer. J Exp Clin Cancer Res 1996; 15: 23-32.
43. Chang J, Powles TJ, Allred DC, et al. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 2000; 6: 616-21.
44. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000; 89: 111-7.
45. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351: 1451-67.
46. Vergote I, Neven P, van Dam P, et al. The oestrogen receptor and its selective modulators in gynaecological and breast cancer. Eur J Cancer 2000; 36 (suppl 4): S1-9.
47. Hawkins RA. How best to express oestrogen receptor activity. Eur J Cancer 2000; 36 (suppl 4): S21-3.
48. Leclercq G, Heuson JC. Therapeutic significance of sex-steroid hormone receptors in the treatment of breast cancer. Eur J Cancer 1977; 13: 1205-15.
49. Cappelletti V, Celio L, Bajetta E, et al. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocr Relat Cancer 2004; 11: 761-70.
50. Jaiyesimi IA, Buzdar AU, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13: 513-29.
51. Huang A, Leygue E, Dotzlaw H, et al. Influence of estrogen receptor variants on the determination of ER status in human breast cancer. Breast Cancer Res Treat 1999; 58: 219-25.
52. McGuire WL, Chamness GC, Fuqua SA. Abnormal estrogen receptor in clinical breast cancer. J Steroid Biochem Mol Biol 1992; 43: 243-7.
53. Horwitz KB. Cellular heterogeneity and mutant oestrogen receptors in hormone resistant breast cancer. Cancer Surv 1992; 14: 41-54.
54. Pfeffer U, Fecarotta E, Castagnetta L, et al. Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer Res 1993; 53: 741-3.
55. May E, Mouriesse H, May-Levin F, et al. A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level. Oncogene 1989; 4: 1037-42.
56. May E, Mouriesse H, May-Levin F, et al. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 1990; 62: 430-5.
57. Hopp TA, Weiss HL, Hilsenbeck SG, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004; 10: 2751-60.
58. Jacobsen BM, Schittone SA, Richer JK, et al. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 2005; 19: 574-87.
59. Umekita Y, Ohi Y, Sagara Y, Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 2002; 98: 415-8.
60. Rosen PP, Menendez-Botet CJ, Nisselbaum JS, et al. Pathological review of breast lesions analyzed for estrogen receptor protein. Cancer Res 1975; 35: 3187-94.
61. Antoniades K, Spector H. Correlation of estrogen receptor levels with histology and cytomorphology in human mammary cancer. Am J Clin Pathol 1979; 71: 497-503.
62. Golouh R, Vrhovec I, Braèko M, et al. Comparison of standardized immunohistochemical and biochemical assays for estrogen and progesterone receptors in breast carcinoma. Pathol Res Pract 1997; 193: 543-9.
63. Jeziorski A. Analiza immunologiczna białkowych produktów wybranych onkogenów i genów supresorowych w pierwotnym inwazyjnym raku zrazikowym piersi u kobiet. Akademia Medyczna w Łodzi 2000. s. 46.
64. Helin HJ, Helle MJ, Kallioniemi OP, et al. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry. Cancer 1989; 63: 1761-7.
65. Parl FF, Wagner RK. The histopathological evaluation of human breast cancers in correlation with estrogen receptor values. Cancer 1980; 46: 362-7.
66. Ricketts D, Coombes RC. What's new in steroid receptor immunocytochemistry in clinical oncology? Pathol Res Pract 1989; 185: 935-41.
67. Shousha S, Backhous CM, Alaghband-Zadeh J, et al. Alveolar variant of invasive lobular carcinoma of the breast. A tumor rich in estrogen receptors. Am J Clin Pathol 1986; 85: 1-5.
68. Wong SY, Kernohan NM, Walker F. Breast cancers with extremely high oestrogen receptor protein status. Histopathology 1990; 16: 125-32.
69. Fernö M, Andersson C, Fallenius G, et al. Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. The South Sweden Breast Cancer Group. Acta Oncol 1996; 35: 17-22.
70. Meyer JS, McDivitt RW, Stone KR. Practical breast carcinoma cell kinetics: review and update. Breast Cancer Res Treat 1984; 4: 79-88.
71. Olszewski W, Darzynkiewicz Z, Rosen PP, et al. Flow cytometry of breast carcinoma: II. Relation of tumor cell cycle distribution to histology and estrogen receptor. Cancer 1981; 48: 985-8.
72. Gerdes J, Pickartz H, Brotherton J, et al. Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies. Am J Pathol 1987 Dec; 129: 486-92.
73. Helin ML, Helle MJ, Helin HJ, et al. Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas. Arch Pathol Lab Med 1989; 113: 854-7.
74. Hanna WM, Kahn HJ, Chapman JA. The correlation of Ki67 growth factor and ERICA in breast cancer. Mod Pathol 1992; 5: 220-3.
75. Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer 2004; 11: 267-75.
76. Reiner A, Reiner G, Spona J, et al. Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. A comparison of immunocytochemical and biochemical analysis. Cancer 1988; 61: 1149-54.
77. Neumann K, Rüschoff J, Horstmann J, et al. Korrelation zwischen immunhistochemisch und biochemisch bestimmtem Progesteronrezeptorgehalt sowie Tumorgrading, Tumorausdehnung, Proliferationsrate und Chromatingehalt beim Mammakarzinom. Tumor Diagnostic Therapie 1989; 10: 109-14.
78. Berger U, McClelland RA, Wilson P, et al. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 1991; 51: 239-44.
79. Di Fronzo G, Cappelletti V, Coradini D, et al. Prognostic significance of progesterone receptors alone or in association with estrogen receptors in human breast cancer. Tumori 1984; 70: 159-64.
80. Branković-Magić M, Janković R, Nešković-Konstantinović Z, et al. Progesterone receptor status of breast cancer metastases. J Cancer Res Clin Oncol 2002; 128: 55-60.
81. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998 Jun; 50: 151-96.
82. McInerney JM, Wilson MA, Strand KJ, et al. A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells. J Cell Biochem 2001; 80: 538-49.
83. Branković-Magić MV, Nikolić-Vukosavljević DB, Neśković-Konstantinović ZB, et al. Variations in the content of steroid receptors in breast cancer. Comparison between primary tumors and metastatic lesions. Acta Oncol 1992; 31: 629-33.
84. Lower EE, Glass EL, Bradley DA, et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005; 90: 65-70.
85. Holdaway MI, Mason BH. Does receptor status in breast cancer vary with time, site and treatment? Rev Endocr Relat Cancer 1984; 19: 17-21.
86. Coradini D, Oriana S, Ditto A, et al. Receptor status variation in primary breast cancer and subsequent accessible relapse. Int J Oncol 1996; 8: 997-1002.
87. Crawford DJ, Cowan S, Fitch R, Smith DC, et al. Stability of oestrogen receptor status in sequential biopsies from patients with breast cancer. Br J Cancer 1987; 56: 137-40.
88. Hull DF 3rd, Clark GM, Osborne CK, et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43: 413-6.
89. Spataro V, Price K, Goldhirsch A, et al. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992; 3: 733-40.
90. Hähnel R, Twaddle E. The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas. Breast Cancer Res Treat 1985; 5: 155-63.
91. Davis BW, Zava DT, Locher GW, et al. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol 1984; 20: 375-82.
92. Clarke R, Dickson RB, Brunner N. The process of malignant progression in human breast cancer. Ann Oncol 1990; 1: 401-7.
93. Allemani C, Sant M, Berrino F, et al. Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study. Br J Cancer 2004; 91: 1263-8.
94. Esteban JM, Ahn C, Battifora H, et al. Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer. Am J Clin Pathol 1994; 102 (4 suppl 1): S9-12.
95. Kohail HM, Elias EG, el-Nowiem SA, et al. A multifactorial analysis of steroid hormone receptors in stages I and II breast cancer. Ann Surg 1985; 201: 611-7.
96. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352: 930-42.
97. Clark GM, McGuire WL. The clinical usefulness of estrogen-receptor and other markers of hormone dependence. Proc Royal Soc Edin 1989; 95B: 145-50.
98. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984; 2: 1102-9.
99. Vollenweider-Zerargui L, Barrelet L, Wong Y, et al. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients. Cancer 1986; 57: 1171-80.
100. Williams MR, Todd JH, Ellis IO, et al. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer 1987; 55: 67-73.
101. Alexieva-Figusch J, Van Putten WL, Blankenstein MA, et al. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer 1988; 61: 758-68.
102. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988; 15 (2 suppl. 1): 20-5.
103. Molino A, Turazza M, Bonetti A, et al. Estrogen and progesterone receptors in breast cancer: correlation with clinical and pathological features and with prognosis. Oncology 1992; 49: 82-8.
104. Hupperets SP, Volovics L, Schouten JL, et al. The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer. Am J Clin Oncol 1997; 20: 546-51.
105. Molino A, Micciolo R, Turazza M, et al. Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 1997; 45: 241-9.
106. Thorpe SM, Rose C, Rasmussen BB, et al. Steroid hormone receptors as prognostic indicators in primary breast cancer. Breast Cancer Res Treat 1986; 7 suppl.: S91-7.
107. DeSombre ER, Thorpe SM, Rose C, et al. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res 1986; 46 (8 suppl.): 4256s-64s.
108. Andersen J, Thorpe SM, King WJ, et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 1990; 26: 442-9.
109. Kinsel LB, Szabo E, Greene GL, et al. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 1989; 49: 1052-6.
110. Bejar J, Sabo E, Eldar S, et al. The prognostic significance of the semiquantitatively determined estrogen receptor content of breast carcinomas. A clinicopathological study. Pathol Res Pract 2002; 198: 455-60.
111. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004; 9: 606-16.
112. Gotteland M, May E, May-Levin F, et al. Estrogen receptors (ER) in human breast cancer. The significance of a new prognostic factor based on both ER protein and ER mRNA contents. Cancer 1994; 74: 864-71.
113. Layfield LJ, Saria EA, Conlon DH, et al. Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prognostic significance. J Surg Oncol 1996; 61: 177-84.
114. Chevallier B, Mosseri V, Dauce JP, et al. A prognostic score in histological node negative breast cancer. Br J Cancer 1990; 61: 436-40.
115. Reynolds T. Breast cancer prognostic factors - the search goes on. J Natl Cancer Inst 1994; 86: 480-3.
116. Figueroa JA, Yee D, McGuire WL. Prognostic indicators in early breast cancer. Am J Med Sci 1993; 305: 176-82.
117. Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002; 71: 67-75.
118. Rudolph P, MacGrogan G, Bonichon F, et al. Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat 1999; 55: 61-71.
119. Chua DY, Pang MW, Rauff A, et al. Correlation of steroid receptors with histologic differentiation in mammary carcinoma. A Singapore experience. Cancer 1985; 56: 2228-34.
120. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998; 52: 227-37.
121. Allred DC, Bustamante MA, Daniel CO, et al. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 1990; 125: 107-13.
122. Esteban JM, Ahn C, Battifora H, et al. Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance. J Cell Biochem Suppl 1994; 19: 138-45.
123. Esteban JM, Ahn C, Mehta P, et al. Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol 1994; 102: 158-62.
124. Jonat W, Maass H, Stegner HE. Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res 1986; 46 (8 suppl.): 4296s-8s.
125. Kommoss F, Pfisterer J, Idris T, et al. Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. Anal Quant Cytol Histol 1994; 16: 203-10.
126. Marchetti E, Querzoli P, Moncharmont B, et al. Immunocytochemical demonstration of estrogen receptors by monoclonal antibodies in human breast cancer: correlation with estrogen receptor assay by dextran-coated charcoal method. Cancer Res 1987; 47: 2508-13.
127. Querzoli P, Ferretti S, Marzola A, et al. Clinical usefulness of estrogen receptor immunocytochemistry in human breast cancer. Tumori 1992; 78: 287-90.
128. Reiner A, Neumeister B, Reiner G, et al. Jakesz R, Kolb R, Schemper M, Spona J. Steroidhormonrezeptoren im Mammakarzinom. Immunohistochemischer Nachweis und prognostische Bedeutung. Zentralbl Pathol 1991; 137: 233-41.
129. Gordts SL, Neven P, Van Hooff I, et al. The immunocytochemical versus cytosol measurement of the oestrogen receptor in invasive breast cancer tissue. Eur J Cancer 2000; 36 (suppl. 4): S20-1.
130. De Mascarel I, Soubeyran I, MacGrogan G, et al. Immunohistochemical analysis of estrogen receptors in 983 breast carcinomas. Concordance with biochemical assay and prognostic significance. Appl Immunohistochem 1995; 3: 223-31.
131. MacGrogan G, Soubeyran I, de Mascarel I, et al. Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas. Appl Immunohistochem 1996; 4: 219-27.
132. Cudahy TJ, Boeryd BR, Franlund BK, et al. A comparison of three different methods for the determination of estrogen receptors in human breast cancer. Am J Clin Pathol 1988; 90: 583-90.
133. Katz RL, Patel S, Sneige N, et al. Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res Treat 1990; 15: 191-203.
134. Pertschuk LP, Eisenberg KB, Carter AC, et al. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer 1985; 55: 1513-8.
135. McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-21.
136. Pascal RR, Santeusanio G, Sarrell D, et al. Immunohistologic detection of estrogen receptors in paraffin-embedded breast cancers: correlation with cytosol measurements. Hum Pathol 1986; 17: 370-5.
137. Sondergaard G, Pedersen KO, Paulsen SM. Estrogen receptor analyses in breast cancer: comparison of monoclonal immunohistochemical and biochemical methods. Eur J Cancer Clin Oncol 1989; 25: 1425-9.
138. Patterson DA, Reid CP, Anderson TJ, et al. Assessment of oestrogen receptor content of breast carcinoma by immunohistochemical techniques on fixed and frozen tissue and by biochemical ligand binding assay. J Clin Pathol 1990; 43: 46-51.
139. Rasmussen BB, Thorpe SM, Norgaard T, et al. Immunohistochemical steroid receptor detection in frozen breast cancer tissue. A multicenter investigation. Acta Oncol 1988; 27 (6A): 757-60.
140. De Lena M, Marzullo F, Simone G, et al. Correlation between ERICA and DCC assay in hormone receptor assessment of human breast cancer. Oncology 1988; 45: 308-12.
141. Hanna W, Mobbs BG. Comparative evaluation of ER-ICA and enzyme immunoassay for the quantitation of estrogen receptors in breast cancer. Am J Clin Pathol 1989; 91: 182-6.
142. Wong SY, Carrol ED, Ah-See SY, et al. Detection of estrogen receptor proteins in breast tumors using an improved APAAP immunohistochemical technique. Cancer 1988; 62: 2171-5.
143. Parl FF, Posey YF. Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. Hum Pathol 1988; 19: 960-6.
144. Scheres HM, De Goeij AF, Rousch MJ, et al. Quantification of oestrogen receptors in breast cancer: radiochemical assay on cytosols and cryostat sections compared with semiquantitative immunocytochemical analysis. J Clin Pathol 1988; 41: 623-32.
145. Helin HJ, Helle MJ, Helin ML, et al. Immunocytochemical detection of estrogen and progesterone receptors in 124 human breast cancers. Am J Clin Pathol 1988; 90: 137-42.
146. Alberts SR, Ingle JN, Roche PR, et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 1996; 78: 764-72.
147. Huang A, Pettigrew N, Watson P. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol 1996; 180: 223-7.
148. Nedergaard L, Christensen L, Rasmussen BB, et al. Comparison of two monoclonal antibodies for the detection of estrogen receptors in primary breast carcinomas. Pathol Res Pract 1996; 192: 983-8.
149. King WJ, DeSombre ER, Jensen EV, et al. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res 1985; 45: 293-304.
150. Wilbur DC, Willis J, Mooney RA, et al. Estrogen and progesterone receptor detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunohistochemistry with the dextran-coated charcoal assay. Mod Pathol 1992; 5: 79-84.
151. Leake R. Detection of the oestrogen receptor (ER). immunohistochemical versus cytosol measurements. Eur J Cancer 2000; 36 (suppl. 4): S18-9.
152. Barnes DM, Millis RR, Beex LV, et al. Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer 1998; 34: 1677-82.
153. Robertson JFR, Bates K, Pearson D, et al. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 1992; 65: 727-30.
154. Beck T, Weikel W, Brumm C, et al. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Gynecol Oncol 1994; 53: 220-7.
155. Andersen J, Poulsen HS. Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 1989; 64: 1901-8.
156. Battifora H, Mehta P, Ahn C, et al. Estrogen receptor immunohistochemical assay in paraffin-embedded tissue: A better gold standard? Appl Immunohistochem 1993; 1: 39-45.
157. Battifora H. Immunocytochemistry of hormone receptors in routinely processed tissues. The new gold standard. Appl Immunohistochem 1994; 2: 143-5.
158. Gaskell DJ, Hawkins RA, Sangsterl K, et al. Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet 1989; 1: 1044-6.
159. Hendricks JB, Stephen CA, Wilkinson EJ, et al. Estrogen receptor specific (ER1D5) epitope stability in paraffin sections. J Histotech 1996; 19: 23-5.
160. Taylor CR. Paraffin section immunocytochemistry for estrogen receptor: the time has come. Cancer 1996; 77: 2419-22.
161. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA; sequence, expression and homology to v-erbA. Nature 1986; 320: 134-9.
162. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93: 5925-30.
163. Kuiper G, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863-70.
164. Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. Cancer Res 1999; 59: 5425-8.
165. Gustafsson JA. New insights in oestrogen receptor (ER) research - the ERbeta. Eur J Cancer 2000; 36 (suppl 4): S16.
166. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-8.
167. Pike AC, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999; 18: 4608-18.
168. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140: 5566-78.
169. Fuqua SA, Schiff R, Parra I, et al. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003; 63: 2434-9.
170. Nakopoulou L, Lazaris AC, Panayotopoulou EG, et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 2004; 57: 523-8.
171. Speirs V, Parkes A, Kerin M, et al. Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res 1999; 59: 525-8.
172. Jarvinen T, Pelto-Huikko M, Holli K, et al. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 2000; 156: 29-35.
173. Kraus WL, Weis KE, Katzenellenbogen BS. Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol Cell Biol 1995; 15: 1847-57.
174. Conneely OM, Maxwell BL, Toft DO, et al. The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. Biochem Biophys Res Commun 1987; 149: 493-501.
175. Conneely OM, Kettelberger DM, Tsai MJ, et al. The chicken progesterone receptor A and B isoforms are products of an alternate translation initiation event. J Biol Chem 1989; 264: 14062-4.
176. Wen DX, Xu YF, Mais DE, et al. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 1994; 14: 8356-64.
177. Sartorius CA, Melville MY, Hovland AR, et al. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 1994; 8: 1347-60.
178. Richer JK, Jacobsen BM, Manning NG, et al. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002; 277: 5209-18.
179. Giangrande PH, Kimbrel EA, Edwards DP, et al. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 2000; 20: 3102-15.
180. Horwitz KB. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 1992; 13: 146-63.
181. Shyamala G, Yang X, Silberstein G, et al. Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci U S A 1998; 95: 696-701.
182. Shyamala G Yang X, Cardiff RD, et al. Dale E. Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci USA 2000; 97: 3044-9.
183. Mulac-Jericevic B, Mullinax RA, DeMayo FJ, et al. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000; 289: 1751-4.
184. Mote PA, Johnston JF, Manninen T, et al. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol 2001; 54: 624-30.
185. Seymour L, Meyer K, Esser J, et al. Estimation of PR and ER by immunocytochemistry in breast cancer. Comparison with radioligand binding methods. Am J Clin Pathol 1990; 94 (4 suppl. 1): S35-40.
186. Ariga N, Suzuki T, Moriya T, et al. Progesterone receptor A and B isoforms in the human breast and its disorders. Jpn J Cancer Res 2001; 92: 302-8.
187. Bamberger AM, Milde-Langosch K, Schulte HM, et al. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res 2000; 54: 32-7.
188. Graham JD, Yeates C, Balleine RL, et al. Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 1995; 55: 5063-8.
189. Gasparini G, Pozza F, Dittadi R, et al. Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer. J Cancer Res Clin Oncol 1992; 118: 557-63.
190. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
191. Pertschuk LP, Feldman JG, Eisenberg KB, et al. Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, disease-free survival, and clinical endocrine response. Cancer 1988; 62: 342-9.
192. Vegeto E, Shahbaz MM, Wen DX, et al. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993; 7: 1244-55.
193. Mohamed MK, Tung L, Takimoto GS, et al. The leucine zippers of c-fos and c-jun for progesterone receptor dimerization: A-dominance in the A/B heterodimer. J Steroid Biochem Mol Biol 1994; 51: 241-50.